Farhad Mashayekhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Farhad Mashayekhi has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Zivar Salehi
8 shared publicationsZ. Salehi
University of Guilan
5 shared publications- Ebrahim Mirzajani
Department of Biochemistry, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3 shared publications - Mohammad Naji
Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications - Zivar Salehi
Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran
3 shared publications Farzad Rajaei
Qazvin University of Medical Sciences
2 shared publications
Latest Publications
- 10 December 2018
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 76 (2) , 98-100
BMP4 circulating levels and promoter (rs17563) polymorphism in risk prediction of idiopathic male infertility
(2019). BMP4 circulating levels and promoter (rs17563) polymorphism in risk prediction of idiopathic male infertility. British Journal of Biomedical Science. Ahead of Print.
- 10 December 2018
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 76 (2) , 98-100
BMP4 circulating levels and promoter (rs17563) polymorphism in risk prediction of idiopathic male infertility
(2019). BMP4 circulating levels and promoter (rs17563) polymorphism in risk prediction of idiopathic male infertility. British Journal of Biomedical Science. Ahead of Print.
- 28 November 2018
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 76 (2) , 86-88
Genetic polymorphism of glial cell-derived neurotrophic factor (GDNF) in male infertility
(2018). Genetic polymorphism of glial cell-derived neurotrophic factor (GDNF) in male infertility. British Journal of Biomedical Science. Ahead of Print.
- 28 November 2018
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 76 (2) , 86-88
Genetic polymorphism of glial cell-derived neurotrophic factor (GDNF) in male infertility
(2018). Genetic polymorphism of glial cell-derived neurotrophic factor (GDNF) in male infertility. British Journal of Biomedical Science. Ahead of Print.
- Open Access
- 1 January 2016
- Published by Termedia Sp. z.o.o. in Folia Neuropathologica
- Vol. 3 (3) , 259-264
Administration of vitamin D 3 induces CNPase and myelin oligodendrocyte glycoprotein expression in the cerebral cortex of the murine model of cuprizone-induced demyelination
In the central nervous system (CNS) the main proteins of myelin are proteolipid protein (PLP), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and CNPase. Myelin oligodendrocyte glycoprotein is a minor component of the myelin sheath, but is an important autoantigen linked to...
- 1 January 2016
- Published by Termedia Sp. z.o.o. in Folia Neuropathologica
- Vol. 3 (3) , 259-264
Open AccessAdministration of vitamin D 3 induces CNPase and myelin oligodendrocyte glycoprotein expression in the cerebral cortex of the murine model of cuprizone-induced demyelination
In the central nervous system (CNS) the main proteins of myelin are proteolipid protein (PLP), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and CNPase. Myelin oligodendrocyte glycoprotein is a minor component of the myelin sheath, but is an important autoantigen linked to...
- 1 January 2015
- Published by Pleiades Publishing Ltd in Molecular Biology
- Vol. 49 (1) , 168-170
The association between the DAZ T > C polymorphism and idiopathic male infertility risk in the north of Iran
- 1 January 2015
- Published by Pleiades Publishing Ltd in Molecular Biology
- Vol. 49 (1) , 168-170
The association between the DAZ T > C polymorphism and idiopathic male infertility risk in the north of Iran
- Open Access
- 1 January 2015
- Published by Termedia Sp. z.o.o. in Folia Neuropathologica
- Vol. 2 (2) , 147-152
Original paper Administration of leukemia inhibitory factor increases Opalin and myelin oligodendrocyte glycoprotein expression in the cerebral cortex in a cuprizone-induced model of demyelination
Multiple sclerosis (MS) lesions are characterized by inflammatory demyelination and reactive gliosis, and although remyelination occurs in some lesions it is limited and incomplete. Leukemia inhibitory factor (LIF) is an important cytokine that stimulates oligodendrocyte proliferation and...
- 1 January 2015
- Published by Termedia Sp. z.o.o. in Folia Neuropathologica
- Vol. 2 (2) , 147-152
Open AccessOriginal paper Administration of leukemia inhibitory factor increases Opalin and myelin oligodendrocyte glycoprotein expression in the cerebral cortex in a cuprizone-induced model of demyelination
Multiple sclerosis (MS) lesions are characterized by inflammatory demyelination and reactive gliosis, and although remyelination occurs in some lesions it is limited and incomplete. Leukemia inhibitory factor (LIF) is an important cytokine that stimulates oligodendrocyte proliferation and...
- 16 August 2014
- Published by Springer Nature in Tumor Biology
- Vol. 35 (11) , 11489-11497
Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer
Breast cancer is the most common cancer among women in the world. One of the approaches for diagnosis of breast cancer is detection of its tumor-associated markers. Mucin 1 (MUC1), a tumor-associated antigen, is a transmembrane glycoprotein expressed by normal epithelial cells and overexpressed by carcinomas of epithelial origin. Also, human epidermal growth factor receptor-2 (HER2/erbB-2) belongs to the one of four members of tyrosin kinase type 1 family in which overexpression of HER2 is associated with malignancy in breast cancer. This study was aimed to bioinformatics analysis and designing a recombinant chimeric protein containing MUC1 and HER2 antigens to express in prokaryotic host (Escherichia coli) as breast cancer diagnosis tools. The immunogenic sequences of MUC1 and HER2 were extracted and fused together by a linker. The chimeric construct was analyzed by bioinformatics softwares. The optimization and purification, evaluation of the expression of chimeric protein was performed using Western blotting, ELISA, and immunohistochemistry. The results showed that the chimeric construct was stable and immunogenic domains were exposed. The pET-28a vector containing chimeric gene had high level of protein expression. The recombinant chimeric protein was confirmed using Western blotting, and it was investigated using ELISA and IHC. Then, the MUC1 and HER2 combined peptides can be used as coating antigens in ELISA for detection of antibodies against MUC1 or HER2 in human serum.
- 16 August 2014
- Published by Springer Nature in Tumor Biology
- Vol. 35 (11) , 11489-11497
Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer
Breast cancer is the most common cancer among women in the world. One of the approaches for diagnosis of breast cancer is detection of its tumor-associated markers. Mucin 1 (MUC1), a tumor-associated antigen, is a transmembrane glycoprotein expressed by normal epithelial cells and overexpressed by carcinomas of epithelial origin. Also, human epidermal growth factor receptor-2 (HER2/erbB-2) belongs to the one of four members of tyrosin kinase type 1 family in which overexpression of HER2 is associated with malignancy in breast cancer. This study was aimed to bioinformatics analysis and designing a recombinant chimeric protein containing MUC1 and HER2 antigens to express in prokaryotic host (Escherichia coli) as breast cancer diagnosis tools. The immunogenic sequences of MUC1 and HER2 were extracted and fused together by a linker. The chimeric construct was analyzed by bioinformatics softwares. The optimization and purification, evaluation of the expression of chimeric protein was performed using Western blotting, ELISA, and immunohistochemistry. The results showed that the chimeric construct was stable and immunogenic domains were exposed. The pET-28a vector containing chimeric gene had high level of protein expression. The recombinant chimeric protein was confirmed using Western blotting, and it was investigated using ELISA and IHC. Then, the MUC1 and HER2 combined peptides can be used as coating antigens in ELISA for detection of antibodies against MUC1 or HER2 in human serum.
- 28 March 2014
- Published by Springer Nature in Surgery Today
- Vol. 45 (2) , 215-220
The soluble VEGFR1 concentration in the serum of patients with colorectal cancer
VEGFR is involved in complex biological processes, including inflammation and cancer development, progression and metastasis. Many proteins, including VEGFR, are proteolytically released from the surface of cells by a process known as ectodomain shedding. The aim of this study was to assess the expression of soluble VEGFR1 (sVEGFR1) in the serum of patients with colorectal cancer (CRC). Sixty-two serum samples from healthy controls and 88 samples from patients with different stages of CRC were included in this study. The total protein concentration (TPC) was measured using a Bio-Rad protein assay, and the expression and concentration of sVEGFR1 was determined by a Western blot analysis and enzyme-linked immunosorbent assay, respectively. No significant difference in the serum TPC of patients with and without CRC was seen. The relative s-VEGFR1 expression and concentration of sVEGFR1 in the serum of patients with CRC were significantly increased compared to those in controls (P < 0.001). The results of this study suggest that VEGFR1 shedding may provide a reliable and practical indicator of the malignant potential, tumor progression and overall tumor burden. The findings also suggest that sVEGFR1 might be involved in the pathophysiology of CRC, and the detection of serum sVEGFR1 may be useful in classifying CRC.
- 28 March 2014
- Published by Springer Nature in Surgery Today
- Vol. 45 (2) , 215-220
The soluble VEGFR1 concentration in the serum of patients with colorectal cancer
VEGFR is involved in complex biological processes, including inflammation and cancer development, progression and metastasis. Many proteins, including VEGFR, are proteolytically released from the surface of cells by a process known as ectodomain shedding. The aim of this study was to assess the expression of soluble VEGFR1 (sVEGFR1) in the serum of patients with colorectal cancer (CRC). Sixty-two serum samples from healthy controls and 88 samples from patients with different stages of CRC were included in this study. The total protein concentration (TPC) was measured using a Bio-Rad protein assay, and the expression and concentration of sVEGFR1 was determined by a Western blot analysis and enzyme-linked immunosorbent assay, respectively. No significant difference in the serum TPC of patients with and without CRC was seen. The relative s-VEGFR1 expression and concentration of sVEGFR1 in the serum of patients with CRC were significantly increased compared to those in controls (P < 0.001). The results of this study suggest that VEGFR1 shedding may provide a reliable and practical indicator of the malignant potential, tumor progression and overall tumor burden. The findings also suggest that sVEGFR1 might be involved in the pathophysiology of CRC, and the detection of serum sVEGFR1 may be useful in classifying CRC.
- 1 March 2014
- Published by Springer Nature in Neurological Sciences
- Vol. 35 (8) , 1243-1247
Effects of electromagnetic fields on Reelin and Dab1 expression in the developing cerebral cortex
Many studies describe the biological effects of electromagnetic fields (EMF) including brain damages, neuronal migration and neurogenesis within the central nervous system. Neuronal cell produced in the neuroepithelium migrates along radial glial fibers into the cortical plate. Reelin, which is produced by Cajal–Retzius cells directs neuronal migration. It was shown that Disabled 1 (Dab1) functions downstream of reelin signal transduction pathway that directs the correct cytoarchitecture of the developing cortex. In this study, the EMF effects on total protein concentration (TPC), reelin and Dab1 expression in the developing cortex was studied. 30 pregnant Balb/c mice were separated into three groups: control (n = 10), EMF (n = 10) and SHAM groups (n = 10). The 15-day pregnant mice were placed inside the solenoid for a daily EMF exposure of 5 h for 3 consecutive days (15–17). The SHAM group was also located in the same coil with no exposure. Mice were sacrificed 24 h after the final exposure session. TPC, reelin and Dab1 expression were studied by Bio-Rad protein assay and western blot. No significant change in the TPC was seen in the EMF-treated cerebral cortex samples compared with those from the SHAM and control groups. It was also shown that the reelin and Dab1 expression increases in the EMF-treated cerebral cortex extracts as compared to controls and SHAM group. It is concluded that EMF may play important role in the neural cell migration by increasing reelin and Dab1 expression in the developing cortex.
- 1 March 2014
- Published by Springer Nature in Neurological Sciences
- Vol. 35 (8) , 1243-1247
Effects of electromagnetic fields on Reelin and Dab1 expression in the developing cerebral cortex
Many studies describe the biological effects of electromagnetic fields (EMF) including brain damages, neuronal migration and neurogenesis within the central nervous system. Neuronal cell produced in the neuroepithelium migrates along radial glial fibers into the cortical plate. Reelin, which is produced by Cajal–Retzius cells directs neuronal migration. It was shown that Disabled 1 (Dab1) functions downstream of reelin signal transduction pathway that directs the correct cytoarchitecture of the developing cortex. In this study, the EMF effects on total protein concentration (TPC), reelin and Dab1 expression in the developing cortex was studied. 30 pregnant Balb/c mice were separated into three groups: control (n = 10), EMF (n = 10) and SHAM groups (n = 10). The 15-day pregnant mice were placed inside the solenoid for a daily EMF exposure of 5 h for 3 consecutive days (15–17). The SHAM group was also located in the same coil with no exposure. Mice were sacrificed 24 h after the final exposure session. TPC, reelin and Dab1 expression were studied by Bio-Rad protein assay and western blot. No significant change in the TPC was seen in the EMF-treated cerebral cortex samples compared with those from the SHAM and control groups. It was also shown that the reelin and Dab1 expression increases in the EMF-treated cerebral cortex extracts as compared to controls and SHAM group. It is concluded that EMF may play important role in the neural cell migration by increasing reelin and Dab1 expression in the developing cortex.
- 12 November 2013
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 289 (5) , 1107-1112
Soluble c-Met expression in the peritoneal fluid and serum of patients with different stages of endometriosis
Introduction Hepatocyte growth factor (HGF), also known as scatter factor, and its receptor c-Met have been shown to be implicated in endometriosis. HGF acts as a mitogen, motogen, and morphogen on endometrial epithelial cells. The expression of c-Met on human endometrial cells has been reported. Many proteins are proteolytically released from the surface by a process known as ectodomain shedding. The aim of this study was to determine the levels of soluble c-Met (s-cMet) in the peritoneal fluid (PF) and serum samples of patients with different stages of endometriosis. Material and methods 39 PF and serum samples from normal healthy and 130 samples from different stages of patients with endometriosis (33 cases of stage I, 38 stage II, 30 stage III and 29 stage IV) were included in this study. Total protein concentration (TPC) and the level of s-cMet in the PF and serum were determined by Bio-Rad protein assay based on the Bradford dye procedure and enzyme-linked immunosorbent assay, respectively. Results No significant change in the TPC was seen in the serum and PF of patients with endometriosis when compared with normal controls. Results obtained demonstrated that all PF and serum samples presented s-cMet expression, whereas, starting from stages I to IV endometriosis, a significant increase of s-cMet expression was observed as compared to controls. Conclusion The results of this study show that a high expression of s-cMet is correlated with advanced stages of endometriosis. It is also concluded that the detection of serum and PF s-cMet may be useful in classifying endometriosis.
- 12 November 2013
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 289 (5) , 1107-1112
Soluble c-Met expression in the peritoneal fluid and serum of patients with different stages of endometriosis
Introduction Hepatocyte growth factor (HGF), also known as scatter factor, and its receptor c-Met have been shown to be implicated in endometriosis. HGF acts as a mitogen, motogen, and morphogen on endometrial epithelial cells. The expression of c-Met on human endometrial cells has been reported. Many proteins are proteolytically released from the surface by a process known as ectodomain shedding. The aim of this study was to determine the levels of soluble c-Met (s-cMet) in the peritoneal fluid (PF) and serum samples of patients with different stages of endometriosis. Material and methods 39 PF and serum samples from normal healthy and 130 samples from different stages of patients with endometriosis (33 cases of stage I, 38 stage II, 30 stage III and 29 stage IV) were included in this study. Total protein concentration (TPC) and the level of s-cMet in the PF and serum were determined by Bio-Rad protein assay based on the Bradford dye procedure and enzyme-linked immunosorbent assay, respectively. Results No significant change in the TPC was seen in the serum and PF of patients with endometriosis when compared with normal controls. Results obtained demonstrated that all PF and serum samples presented s-cMet expression, whereas, starting from stages I to IV endometriosis, a significant increase of s-cMet expression was observed as compared to controls. Conclusion The results of this study show that a high expression of s-cMet is correlated with advanced stages of endometriosis. It is also concluded that the detection of serum and PF s-cMet may be useful in classifying endometriosis.
- Open Access
- 1 January 2012
- Published by Charles University in Prague, Karolinum Press in Acta Medica (Hradec Kralove, Czech Republic)
- Vol. 55 (2) , 83-86
Quantitative Analysis of Cerebrospinal Fluid Brain Derived Neurotrophic Factor in the Patients with Multiple Sclerosis
Multiple sclerosis (MS) is the most common cause of nontraumatic neurological disability in Europe and North America. Growth factor expression could participate in the repair process of the demyelinating disease. Among growth factors, brain derived neurotrophic factors (BDNF) has been demonstrated to play an important role in neuronal and axonal survival. In the central nervous system (CNS), neurons are the main source of BDNF. Another potential source are activated astrocytes, which are present in inflamed areas in the CNS as shown in MS. In this study, total protein concentration (TPC) and BDNF levels in the cerebrospinal fluid (CSF) samples from the patients with MS (n = 48) and control subjects (n = 53) were measured using a Bio-Rad protein assay and enzyme linked immunosorbent assay (ELISA). No significant change in the CSF TPC of patients with MS was seen as compared to normal CSF. The presence of BDNF in the CSF samples was shown by Western blot. Using ELISA, it was shown that the level of BDNF in the MS CSF is higher than in normal CSF. It is concluded that BDNF is a constant component of human CSF. Moreover, it could be implicated in the pathophysiology of MS.
- 1 January 2012
- Published by Charles University in Prague, Karolinum Press in Acta Medica (Hradec Kralove, Czech Republic)
- Vol. 55 (2) , 83-86
Open AccessQuantitative Analysis of Cerebrospinal Fluid Brain Derived Neurotrophic Factor in the Patients with Multiple Sclerosis
Multiple sclerosis (MS) is the most common cause of nontraumatic neurological disability in Europe and North America. Growth factor expression could participate in the repair process of the demyelinating disease. Among growth factors, brain derived neurotrophic factors (BDNF) has been demonstrated to play an important role in neuronal and axonal survival. In the central nervous system (CNS), neurons are the main source of BDNF. Another potential source are activated astrocytes, which are present in inflamed areas in the CNS as shown in MS. In this study, total protein concentration (TPC) and BDNF levels in the cerebrospinal fluid (CSF) samples from the patients with MS (n = 48) and control subjects (n = 53) were measured using a Bio-Rad protein assay and enzyme linked immunosorbent assay (ELISA). No significant change in the CSF TPC of patients with MS was seen as compared to normal CSF. The presence of BDNF in the CSF samples was shown by Western blot. Using ELISA, it was shown that the level of BDNF in the MS CSF is higher than in normal CSF. It is concluded that BDNF is a constant component of human CSF. Moreover, it could be implicated in the pathophysiology of MS.